Östrogen- und Progesteronrezeptoren in malignen Ovarialtumoren

Abstract

Estrogen receptors (ER) and progesterone receptors (PR) were evaluated in 173 primary ovarian cancers and in 6 ovarian metastases. In epithelial ovarian carcinomas 63% had ER and 46% PR. Almost all granulosa cell tumours were receptor-positive, while sarcomas, dysgerminomas, and teratomas lacked ER and PR. Both receptors were found less often in tumours of the histological grade I than in those of grade II and III. During the development of metastases and during chemotherapy there was a loss of PR in 27% and 53% of the cases, respectively, while the amount of ER remained more or less constant. In addition to ovarian cancers ER and PR were present in carcinomas of the fallopian tube as well. ER-negative and especially PR-negative tumours seemed to respond better to chemotherapy than receptor-positive carcinomas. The possible significance of ER and PR with regard to the success of an endocrine treatment is discussed.

Endocrine Factors in Common Epithelial Ovarian Cancer*

“…1 tain more frequently PR, often in association with ER (98,103,105,108,114), while serous tumors were more frequently found to be ER-positive (101,108,118). In mucinous (101,103,105) and in clear cell tumors (108,109) lower amounts of steroid receptors were detected. Nestok et al (120) did not find a correlation between the presence of ER and PR and histological features.…”

“…However, detailed analysis showed that tumors with a solid growth pattern were more frequently PR-positive and that tumors with a high degree of fibrosis and/or inflammation were frequently PR-negative (120). Some investigators found an association between positivity for ER and poor differentiation (98,108). Others found that well differentiated tumors more frequently contained ER (103,113) or both ER and PR (101,135).…”

“…In metastases or recurrences of ovarian carcinomas, steroid receptors are rarely seen when the primary tumor is receptor-negative (89,90,99,102,108,109,112,131).…”

Estrogen receptor gene amplification occurs rarely in ovarian cancer

“…Depending on the study estrogen receptor expression has been reported in 25-86% of ovarian cancers with the highest percentages reported in endometroid and serous subtypes. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] Accordingly, endocrine therapy is a recognized option in the treatment of chemoresistant ovarian cancer after the failure of first-and second-line therapies. However, not all estrogen receptor-positive ovarian cancers respond to antiestrogen therapy, and it was suggested that it might be because of the facts that most of the studies have been retrospective, small in size without adequate selection of the patients and generally used hormonal therapy as a last-line therapy for the refractory or resistant ovarian cancers.…”

Ovarian carcinoma of hypercalcemic type: myoid features and lack of estrogen and progesterone receptors

“…Unlike OCHT, undifferentiated ovarian carcinomas (that can mimic OCHT) have not been described to express myoid markers. With respect to hormone receptors, some undifferentiated surface-epithelial carcinomas contain ERs and/or PRs [9]. Expression of receptors was described also in the sex cord-stromal cell tumors [7].…”